SecBot SecBot
8-K ·Filed May 6, 2026

TCRX

TScan Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed6mo ago SEC0001193125-26-207549
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

This is a pre-revenue clinical-stage biotech, the earnings miss vs consensus is secondary to upcoming catalysts. The key events to watch are the Phase 3 initiation and early Cohort C data from the ALLOHA trial, both expected in Q2 2026. Positive data could drive significant upside given the $73M market cap, while delays or negative readouts would pressure the stock. Cash burn of ~$24M/quarter provides ~5 quarters of runway.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.25
T+0 close · May 6, 2026 · via day close
Latest settled
−40.56%
T+60 · $0.7430
Vs SPY
−42.62%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 6 $1.25entry
  2. T+1 · 6mo ago −3.20%α −2.87% · $1.21
  3. T+5 · 6mo ago −8.00%α −9.13% · $1.15
  4. T+20 · 6mo ago −22.24%α −25.02% · $0.9720
  5. T+60 · 4mo ago −40.56%α −42.62% · $0.7430
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

TScan Therapeutics reported Q1 2026 revenue of $1.0M (down 55% YoY from $2.2M) and a net loss of $28.7M ($-0.22 EPS), slightly better than the $-0.26 EPS in Q1 2025 but a miss vs the $-0.17 consensus estimate. The company reiterated upcoming catalysts including Phase 3 initiation for TSC-101 and early Cohort C data in Q2 2026, while cash burn continues with $128.1M remaining, funding operations into H2 2027.

Key Financial Metrics

EPS
−$0.22
est −$0.17 · -29.4%
Revenue
$982.0K
est $2.5M · -60.7% · -54.8% YoY
Rating
miss

Key Facts

  • Q1 2026 revenue $1.0M vs $2.2M YoY, down 55% due to Amgen collaboration timing
  • Net loss $28.7M ($-0.22 EPS) vs $34.1M ($-0.26 EPS) in Q1 2025
  • EPS of $-0.22 missed consensus estimate of $-0.17
  • Cash and equivalents $128.1M at March 31, 2026, down from $152.4M at year-end 2025
  • Cash runway into H2 2027 unchanged from prior guidance
  • Phase 3 study of TSC-101 (ALLOHA-2) planned for Q2 2026
  • Early Cohort C data from ALLOHA Phase 1 trial expected in Q2 2026
  • Phase 1 study of TSC-102-A01/A03 targeting CD45 planned for H2 2026
  • Pro forma shares outstanding flat at ~129.9M

Financial Impact

Revenue decline of $1.2M YoY (55%) driven by Amgen collaboration timing; net loss improved by $5.4M YoY due to lower R&D spend

revenuenet losscash position

Risk Factors

  • Clinical trial failure or delay for TSC-101 Phase 3 or TSC-102 Phase 1
  • Revenue concentration on single Amgen collaboration agreement
  • Cash burn rate may require additional financing before H2 2027
  • Pre-funded warrant dilution overhang (~70M warrants at $0.0001/share)

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
77% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-207549
Document: tcrx-20260506.htm0001193125-26-207549
Document: 0001193125-26-207549-index-headers.html0001193125-26-207549
Document: 0001193125-26-207549-index.html0001193125-26-207549
Document: 0001193125-26-207549.txt0001193125-26-207549
8-K Data (Synthetic)0001193125-26-207549

Track record

15 reports on TCRX

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +77.60% at T+60 after the Aug 18, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Bearish 7/10 Entry $0.1680 Now $0.1450 +13.69% settles Nov 19
  2. Oct 26, 202621d ago DEF 14A Bearish 6/10 Entry $0.1897 to $0.1745 Now $0.1450 +23.56% ▲ +8.01% +6.75% vs SPY
  3. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $0.2102 to $0.1897 Now $0.1450 −31.02% ▼ −9.75% −9.61% vs SPY
  4. Sep 30, 20266w ago 8-K Neutral 2/10 Entry $0.3175 to $0.2282 Now $0.1450 −54.33% ▼ −28.13% −29.43% vs SPY
  5. Sep 25, 20267w ago SC 13G Neutral 3/10 Entry $0.3400 to $0.2953 Now $0.1450 −57.35% ▼ −13.15% −14.35% vs SPY
  6. Sep 11, 20269w ago 8-K Neutral 5/10 Entry $0.3204 to $0.3119 Now $0.1450 −54.74% ▼ −2.65% −2.43% vs SPY
  7. Sep 2, 202610w ago 8-K Bearish 7/10 Entry $0.3810 to $0.3179 Now $0.1450 +61.94% ▲ +16.56% +15.60% vs SPY
  8. Aug 18, 202612w ago 8-K Bearish 7/10 Entry $0.7500 to $0.7774 Now $0.1450 +80.67% ▼ −3.65% −4.04% vs SPY
  9. Aug 12, 202613w ago 8-K Bearish 6/10 No price data
  10. Aug 12, 202613w ago Press Release Bearish 6/10 Entry $0.7730 to $0.7500 Now $0.1450 +81.24% ▲ +2.98% +2.53% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 6, 2026